Infliximab Antibody | AbD20436_hIgG1

//www.bio-rad-antibodies.com/infliximab-antibody-abd20436-higg1-hca233.html?RenderPageSpecific=1
Infliximab Antibody | AbD20436_hIgG1 gallery image 1

Human anti infliximab specificity ELISA

A microtiter plate was coated over night with various antigens at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP-conjugated Human anti infliximab (clone AbD20436_hIgG1) at a concentration of 2 µg/ml followed by QuantaBlu fluorogenic peroxidase substrate. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit®

Enlarge
Infliximab Antibody | AbD20436_hIgG1 gallery image 2

Human anti infliximab specificity titration ELISA

A microtiter plate was coated over night with human IgG1/kappa, human IgG1/lambda, cetuximab or infliximab at a concentration of 5 µg/ml. After washing with PBST and blocking with PBST+5% BSA, detection was performed using HRP-conjugated Human anti infliximab (clone AbD20436_hIgG1) titrated to the given concentrations in PBST, followed by QuantaBlu fluorogenic peroxidase substrate. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit®

Enlarge
Infliximab Antibody | AbD20436_hIgG1 gallery image 3

Infliximab bridging ELISA for Pharmacokinetic (PK) assay development

A microtiter plate was coated over night with Human anti infliximab (clone AbD20436, HCA234) at a concentration of 0.6 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of infliximab. Detection was performed using HRP-conjugated Human anti infliximab (clone AbD20436_hIgG1) at a concentration of 2 µg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu fluorogenic peroxidase substrate. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit®

Enlarge
Infliximab Antibody | AbD20436_hIgG1 gallery image 4

Human anti infliximab bridging ELISA for Anti-Drug Antibody (ADA) assay development

A microtitre plate was coated over night with infliximab at a concentration of 1 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of Human anti infliximab (clone AbD20436_hIgG1). Detection was performed using HRP-conjugated infliximab at a concentration of 2 µg/ml in HISPEC assay diluent (BUF049) and QuantaBlu fluorogenic peroxidase substrate. HRP-conjugation of infliximab used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit®

Enlarge
  • Infliximab Antibody | AbD20436_hIgG1 thumbnail image 1
  • Infliximab Antibody | AbD20436_hIgG1 thumbnail image 2
  • Infliximab Antibody | AbD20436_hIgG1 thumbnail image 3
  • Infliximab Antibody | AbD20436_hIgG1 thumbnail image 4
  • Human anti Infliximab
(Rated 0.0 out of 5 based on 0 customer reviews)
    Anti-infliximab antibody is a recombinant, neutralizing, high affinity anti-idiotypic antibody in full IgG1 format, ideal for bioanalytical assays for infliximab and biosimilars. It can be used as the detection antibody in a PK bridging ELISA and as a reference standard in an ADA bridging ELISA.
    • Product Type
      Monoclonal Antibody
    • Clone
      AbD20436_hIgG1
    • Isotype
      IgG1
    1 Formats Available
      Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
      HCA233Edatasheet pdfdatasheet pdf0.1 mg
      HCA233
      Summary
      Secondary Antibodies
      Negative Isotype Controls
      Useful Reagents
      Positive Controls
      Histology Controls
      More Images
      References
      Reviews
      -
      • Human anti Infliximab, clone AbD20436_hIgG1, is an affinity matured anti-idiotypic antibody that specifically recognizes free infliximab but not infliximab bound to its target, Tumor Necrosis Factor Alpha (TNFα). It can be used in bioanalytical assays to measure the levels of infliximab and biosimilar products in patient samples.

        Clone AbD20436_hIgG1 inhibits the binding of infliximab to TNFα and can be used as a detection antibody in a pharmacokinetic (PK) assay in the bridging format to measure free drug. As it is a fully human antibody, it can also be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera.

        Infliximab (branded as Remicade®) is a chimeric IgG1 kappa monoclonal antibody approved for the treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis. This therapeutic antibody is directed against TNFα and acts by blocking the binding of TNFα to its receptors, resulting in a down-regulation of the inflammatory response associated with autoimmune diseases.

        View a summary of all anti-infliximab antibodies.
      • Intended Use
      • Product Form
        Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. This product is supplied as a liquid.
      • Reconstitution
      • Preparation
        Purified IgG prepared by affinity chromatography on Protein A
      • Preservative Stabilisers
        0.01% Thiomersal
      • Immunogen
        Infliximab.
      • Purity
      • Affinity
        The monovalent intrinsic affinity of this antibody was measured as KD=0.12 nM by real time, label-free molecular interaction analysis on immobilized infliximab.
      • Approx. Protein Concentrations
        Antibody concentration 0.5 mg/ml
      • Reagents In The Kit
      • Preparing The Antibody
      • Test Principle
      • Buffer Solution
        Phosphate buffered saline
      • Storage
        Store at +4oC or at -20oC if preferred.
        Storage in frost-free freezers is not recommended.
        This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
      • Shelf Life
        12 months from date of despatch
      • Acknowledgements
        Sold under license of U.S. Patents 6,300,064, 6,696,248, 6,708,484, 6,753,136, European Patent 0,859,841 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany, a wholly owned subsidiary of Bio-Rad Laboratories Inc.

        Remicade is a registered trademark of Janssen Biotech Inc.
      • Licensed Use
        For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
      • Regulatory
        For research purposes only
      • This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.

      • Application NameYesNoMin DilutionMax Dilution
        ELISA

      • Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
      • Technical Advice
        Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
      • Recommended Protocol
      • ELISA
        This product may be used in a direct ELISA or as a bridging antibody in ADA assay development.
        Protocol: PK bridging ELISA to measure free drug
        Protocol: ADA bridging ELISA
      • Immunohistology
      • Histology Positive Control Tissue
      • Immunofluorescence
      • Western Blotting
      • Instructions For Use

      Additional Infliximab Antibody Formats

      Formats Clone Applications Sizes available
      Infliximab Antibody : Purified AbD20436_hIgG1 E 0.1 mg
      • Copyright © 2016 Bio-Rad

      Recommended Secondary Antibody

        Recommended Negative Isotype Control

          Useful Reagents

            DescriptionProduct CodePack SizeApplicationsList PriceQuantity
            LYNX Rapid HRP Antibody Conjugation KitLNK002P3 Conjugations For 400µg AntibodyCJ
            LNK002P
            Human anti InfliximabHCA2340.1 mgE
            HCA234
            Hispec Assay DiluentBUF049A50 mlIY
            BUF049A

            Recommended Positive Controls

              Histology Controls

                References

                Write your review

                You may also be interested in...